512 related articles for article (PubMed ID: 26655953)
1. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Gai Z; Gui T; Hiller C; Kullak-Ublick GA
J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
[TBL] [Abstract][Full Text] [Related]
2. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
[TBL] [Abstract][Full Text] [Related]
6. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
[TBL] [Abstract][Full Text] [Related]
8. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage.
Gai Z; Chu L; Xu Z; Song X; Sun D; Kullak-Ublick GA
Sci Rep; 2017 Aug; 7(1):9815. PubMed ID: 28852062
[TBL] [Abstract][Full Text] [Related]
10. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
11. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
[No Abstract] [Full Text] [Related]
12. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP; Steinman L
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
[TBL] [Abstract][Full Text] [Related]
13. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
14. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
[TBL] [Abstract][Full Text] [Related]
15. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
[TBL] [Abstract][Full Text] [Related]
16. Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney.
Gai Z; Hiller C; Chin SH; Hofstetter L; Stieger B; Konrad D; Kullak-Ublick GA
Biochim Biophys Acta; 2014 Sep; 1842(9):1870-8. PubMed ID: 25016146
[TBL] [Abstract][Full Text] [Related]
17. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
Wang XX; Jiang T; Shen Y; Caldas Y; Miyazaki-Anzai S; Santamaria H; Urbanek C; Solis N; Scherzer P; Lewis L; Gonzalez FJ; Adorini L; Pruzanski M; Kopp JB; Verlander JW; Levi M
Diabetes; 2010 Nov; 59(11):2916-27. PubMed ID: 20699418
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]